The Real AI Breakthrough Won’t Be ChatGPT

The Flash Report

16 Mar 2026 — 1 min read

It will be whoever turns AI into real-world robotics. And that shift is already underway.

Just look at what Artly is doing. Led by a founder whose previous company was acquired by Amazon, Artly has finally solved a decades-old robotics challenge: enabling robots to learn skills directly through human demonstration.

Instead of months of coding and simulation, Artly’s AI system lets robots master hands-on tasks in as little as 30 minutes simply by watching a human instructor. And it’s already been proven in the real world.

Artly’s flagship robot learned how to make lattes from a World Barista Championship-winning barista. Today, their Barista Bot has served 1M+ drinks to customers at locations operated by brands such as Microsoft and Royal Caribbean, generating over $5M in revenue.

But that’s only the start of their potential. Here’s how Artly is positioned to redefine real-world robotics:

Breakthrough: Their imitation-learning AI teaches robots hands-on tasks in minutes, not months, removing robotics’ biggest bottleneck and unlocking true scalability.
Platform: Their robots run on the same core system, earning recurring software revenue and strengthening their IP with every new task learned, a compounding advantage as they expand.
Opportunity: For a limited time, Artly is offering everyday investors early-stage access, before wider expansion accelerates growth, enterprise partnerships go public, and the company enters new high-demand sectors.

It’s a rare chance to invest at the moment, a scalable robotics platform is stepping into its next chapter.

With real revenue, real customers, and a breakthrough that could move one of the biggest opportunities of the 21st century beyond the lab and into daily life, Artly is scaling fast.

And you can join before Artly scales this tech across industries like hospitality, retail, healthcare, and more, with a $300M annual revenue target by 2030.

Become an early-stage Artly investor today.

This is a paid advertisement for Artly Regulation CF offering. Please read the offering circular at https://invest.artly.ai/

The Biggest Unsolved Problem in Medicine?

Today, over half a billion people battle osteoarthritis. Each year, they spend $240B trying to halt the destruction of joint cartilage. But no cure exists on the market. Not for lack of trying, either. Big Pharma’s spent billions failing. Thankfully, Cytonics may have cracked the code. They discovered the

What if David and Goliath teamed up instead?

That’s what’s currently playing out in the foodservice industry, where industry goliaths Sodexo, Aramark, and Compass Group all partnered with foodtech startup Automated Retail Technologies. Why did they choose ART? With more than 150,000 venues managed by that trio alone, staffing overnight operations is costly and complicated.

The Key to This $500B Market Is in Your Bloodstream

Every year, $240B is spent on treating the symptoms of osteoarthritis, a disease that leads to joint degradation and, eventually, immobility. With 500M people afflicted, its total addressable market is worth over $500B. But not a single therapy has been able to actually stop it. The answer, it turns out,

Superhuman' Pre-IPO Stock Trading Under $1

Have you heard about this sub $1 Pre-IPO company that is making people "Superhumans"? It's all thanks to their new product called Visor. And it's very similar to Jarvis from the movie Iron Man. Investors are calling this a 'massive breakthrough'. But

Read more

The Biggest Unsolved Problem in Medicine?

What if David and Goliath teamed up instead?

The Key to This $500B Market Is in Your Bloodstream

Superhuman' Pre-IPO Stock Trading Under $1